Observational studyEpilepsia2026
Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus.
Observational study in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study was undertaken to identify novel blood-based biomarkers associated with the early diagnosis of status epilepticus (SE) by exploring proteomic alterations in plasma extracellular vesicles (EVs).
methodsWe conducted an observational and prospective study in a two-phase design: a discovery proteomic analysis of plasma EVs from 16 patients (eight with SE and eight matched non-SE), followed by a validation phase using basic immunodetection techniques in a separate cohort of 160 patients (80 SE, 80 non-SE) for selected proteins in plasma. Proteomic profiling was performed with liquid chromatography-tandem mass spectrometry, and protein interaction networks were explored using STRING and Cytoscape software platforms.
resultsIn the discovery phase, 2046 proteins were identified, and 977 met inclusion criteria. CDH1, APOC4, and IGHG2 showed the highest differential expression in SE patients. Network analysis revealed strong interactions involving SLC4A1 and SRC. In the validation cohort, levels of APOC4, CDH1, SLC4A1, and S100B were significantly higher in SE patients (p < .05). In the multivariate logistic regression model, only APOC4, S100B, and SLC4A1 remained independently associated with SE diagnosis. A combined model including these proteins predicted SE with 84.6% accuracy (95% confidence interval = 64.3%-94.9%). Other proteins, including NSE and HMGB1, showed no significant differences. SIGNIFICANCE: This study identifies new plasma biomarkers that may support the early diagnosis of SE, particularly in emergency settings where access to electroencephalography is limited. These findings suggest potential applicability to clinical practice; nevertheless, prospective validation in independent and larger cohorts is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.